These findings suggest that compound 16 might be a potent anticancer candidate for HCC treatment by downregulating the expression of the IL-6 gene that causes suppression of the JAK/STAT pathway, decreases inflammation, and tumorigenesis with favorable binding interaction and bioavailability. Here, SOAT1 is linked to hepatocellular carcinoma.